Comprehensive Review
Epidemiology of Febrile Neutropenia

https://doi.org/10.3816/SCT.2003.n.002Get rights and content

Abstract

Febrile neutropenia (FN) continues to represent a major cause of morbidity, mortality, and cost in patients receiving cancer chemotherapy. The reported rates of FN vary considerably among studies depending on the treatment regimen, delivered dose intensity, and patient population. The risk of initial FN appears to be highest during the first cycle of chemotherapy and is greatest in certain high-risk groups including elderly patients and those with various comorbidities. Febrile neutropenia continues to have considerable clinical, economic, and quality-of-life impact on affected patients. The risk of mortality associated with FN continues to be relatively high in patients with hematologic malignancies, patients presenting with comorbid illnesses, and patients with bacteremia, pneumonia, or other infection-related complications. The reduction in chemotherapy dose intensity that frequently follows an episode of FN may have considerable life-threatening impact on disease control in responsive and potentially curable malignancies. The economic burden of FN is substantial, with the greatest proportion of the cost associated with the relatively limited number of patients hospitalized for prolonged periods as a result of comorbidities or complications. The colony-stimulating factors (CSFs) may reduce the risk and cost associated with cancer treatment by reducing the probability of hospitalization with FN. Primary prophylaxis with the CSFs may be warranted in patients receiving intensive regimens or in those at greater risk because of age or comorbidities. Further study of various risk factors for FN should help identify patients at greatest risk and likely candidates for targeted use of the hematopoietic growth factors.

References (79)

  • B Biesma et al.

    Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever

    Eur J Cancer

    (1990)
  • WT Hughes et al.

    2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

    Clin Infect Dis

    (2002)
  • GP Bodey et al.

    Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia

    Ann Intern Med

    (1966)
  • FA Holmes et al.

    Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer

    J Clin Oncol

    (2002)
  • DR Budman et al.

    Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

    J Natl Cancer Inst

    (1998)
  • D Dale et al.

    Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials

    J Natl Compr Cancer Network

    (2003)
  • GK Ellis et al.

    Dose-dense anthracyclinebased chemotherapy for node-positive breast cancer

    J Clin Oncol

    (2002)
  • G Lyman et al.

    Incidence and predictors of low dose intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices

    J Clin Oncol

    (2003)
  • G Lyman et al.

    Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy

    Leuk Lymphoma

    (2003)
  • G Lyman et al.

    Risk and timing of hospitalization for febrile neutropenia among patients receiving CHOP-like regimens for intermediate-grade non-Hodgkin's lymphoma

    Cancer

    (2003)
  • G Lyman et al.

    Risk models for the prediction of chemotherapy-induced neutropenia

    Neutropenia Oncol

    (2001)
  • JH Silber et al.

    First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy

    J Clin Oncol

    (1998)
  • JH Silber et al.

    Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer

    J Clin Oncol

    (1998)
  • JA Talcott et al.

    Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule

    J Clin Oncol

    (1992)
  • Y Kim et al.

    Colony-stimulating factors may reduce complications and death in solid tumor patients with fever and neutropenia

    Proc Am Soc Clin Oncol

    (2000)
  • E Gonzalez-Barca et al.

    Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia

    Eur J Clin Microbiol Infect Dis

    (1999)
  • M Darmon et al.

    Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients

    Intensive Care Med

    (2002)
  • LS Elting et al.

    Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials

    Clin Infect Dis

    (1997)
  • J Carratala et al.

    Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome

    Arch Intern Med

    (1998)
  • G Lyman et al.

    Cost-effectiveness of myeloid growth factors in cancer chemotherapy

    Curr Hematol Rep

    (2003)
  • N Thatcher et al.

    Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party

    J Clin Oncol

    (2000)
  • ML Citron et al.

    Randomized trial of dosedense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

    J Clin Oncol

    (2003)
  • G Lyman

    A predictive model for neutropenia associated with cancer chemotherapy

    Pharmacotherapy

    (2000)
  • E Rivera et al.

    Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model

    Cancer

    (2003)
  • O Agboola et al.

    Risk models for neutropenic complications associated with breast cancer adjuvant chemotherapy

    Proc Am Soc Clin Oncol

    (2002)
  • J Crawford et al.

    The risks and consequences of chemotherapy-induced neutropenia

    Cancer

    (2003)
  • G Lyman

    Risk assessment in oncology practice: from risk factors to risk models

    Oncology

    (2003)
  • G Lyman et al.

    Incorporation of quality of life considerations into decision models for the use of colony stimulating factors in chemotherapy patients at risk for febrile neutropenia

  • B Fortner et al.

    Decline in absolute neutrophil count (ANC) is associated with lower quality of life (QOL) in cancer patients receiving docetaxel

    Proc Am Soc Clin Oncol

    (2002)
  • Cited by (0)

    View full text